7-Valent mRNA Vaccine Reflecting Emerging Variants Rapidly Expands Norovirus Defense Barrier in Primate Studies
Background
Norovirus, a primary pathogen causing acute gastroenteritis, imposes a massive global health burden. It causes severe dehydration and hospitalization in children under 5 and the elderly, with frequent outbreaks. Despite the significant scale of infection and social costs, there are currently no approved commercial vaccines or specific therapeutics from regulatory agencies such as the US FDA.
The main obstacle to vaccine development is the virus's high genetic diversity and continuous antigenic variation. Multiple norovirus genotypes circulate simultaneously, with the strains driving outbreaks constantly shifting over time. Since single-strain antigens struggle to induce broad cross-immunity, designing multivalent vaccines covering various serotypes is essential. In previous studies, researchers designed a pentavalent messenger RNA (mRNA) vaccine candidate expressing VP1 (Viral Protein 1), the capsid protein of five genotypes (GI.1, GII.2, GII.3, GII.4, and GII.6), and confirmed its efficacy in inducing humoral and cellular immunity in mouse and primate models.
The problem is the speed of viral evolution. Recent global surveillance data show a sharp increase in the detection frequency of GI.3 and GII.17 genotypes, emerging as new epidemic variants. A strategy to flexibly expand the existing vaccine composition and broaden the defense range in response to these mutations has become urgent.
Key Findings
Based on surveillance data, researchers newly designed mRNA sequences targeting the VP1 of the emerging GI.3 and GII.17 genotypes. They systematically compared the immunogenicity and cross-reactivity of candidate strains in mouse models to select optimal antigen candidates. Subsequently, they completed a heptavalent formulation by adding the two strains to the existing pentavalent vaccine platform and proceeded with preclinical efficacy evaluations.
Evaluations in mice and African green monkeys (non-human primates) showed that the heptavalent vaccine group exhibited a strong humoral immune response. Serum immunoglobulin G (IgG) antibodies exhibited high binding affinity across all seven genotype virus-like particles (VLPs). Beyond simple binding, distinct neutralizing activity was observed. The antibodies induced by the vaccine effectively blocked the process where VLPs bind to Histo-Blood Group Antigens (HBGAs), which serve as host cell entry receptors.
A major concern in multivalent vaccine development is antigen interference. When multiple antigens are administered simultaneously, immune interference can occur, where the immune response is biased toward a specific antigen or the response to other antigens is suppressed. However, in this heptavalent formulation assessment, the addition of GI.3 and GII.17 components did not significantly inhibit the immune response formed against the original five strains, and signs of immune interference remained extremely limited. Consequently, a balanced functional antibody response targeting all seven genotypes was achieved.
Significance and Outlook
This achievement is significant as it demonstrates the potential for a flexible combination of infectious disease surveillance data and the mRNA vaccine platform. Much like seasonal influenza vaccines, it shows that an update system—capturing emerging dominant variants through surveillance and rapidly expanding them into multivalent formulations—is technically feasible for norovirus. The strength of the mRNA platform, which offers faster process conversion compared to recombinant protein or inactivated virus methods, was clearly demonstrated.
Challenges remain before full clinical application. It must be verified whether the antibody-inducing efficacy and HBGA-blocking activity confirmed in preclinical models directly translate to gastrointestinal mucosal immunity formation and infection prevention in human clinical trials. Due to the nature of gastrointestinal infectious diseases, follow-up studies are required to evaluate the magnitude and duration of secretory immunoglobulin A (sIgA) responses, which protect the intestinal mucosa, alongside serum IgG. Ensuring the long-term storage stability of the complex formulation comprising seven mRNA antigens, as well as optimizing lipid nanoparticle (LNP) formulation, are key challenges that must be carefully addressed in future commercialization efforts.
Noroviruses are a leading cause of acute gastroenteritis and impose a substantial global disease burden, particularly in children younger than 5 years and in older adults. Although multiple vaccine candidates are in preclinical and clinical development, no targeted intervention has been approved. We previously reported that a pentavalent mRNA vaccine candidate encoding VP1 proteins from genotypes GI.1, GII.2, GII.3, GII.4, and GII.6 elicited robust humoral and cellular immune responses in mice and nonhuman primates. Because recent surveillance data indicate increasing prevalence of GI.3 and GII.17, we designed mRNAs targeting these genotypes and evaluated an expanded seven-valent formulation in preclinical studies. We first compared candidate GI.3 and GII.17 strains in mice and selected vaccine components based on immunogenicity and cross-reactivity. The resulting seven-valent mRNA vaccine elicited strong humoral responses in mice and African green monkeys, including serum IgG binding to norovirus virus-like particles (VLPs) and functional antibodies that blocked VLP binding to histo-blood group antigens (HBGAs). Importantly, incorporation of GI.3 and GII.17 broadened functional coverage, whereas multivalent formulation introduced only limited evidence of immune interference. These findings support the feasibility of surveillance-guided updating of multivalent norovirus mRNA vaccines and highlight the adaptability of the mRNA platform for addressing emerging variants. IMPORTANCE Norovirus is a major cause of vomiting and diarrhea worldwide, but developing a broadly protective vaccine is difficult because many genetically distinct strains circulate, and their prevalence changes over time. This study demonstrates a flexible vaccine strategy in which mRNA components can be selected and added based on disease surveillance and experimental evidence. We expanded a five-component norovirus vaccine to include GI.3 and GII.17, two increasingly important genotypes. The resulting
Norovirus causes large-scale outbreaks annually in crowded facilities such as cafeterias, daycare centers, military bases, and cruise ships, and is a leading cause of hospitalization among infants and the elderly. In the absence of commercial vaccines, this 7-valent mRNA vaccine establishes an industrial standard for multivalent vaccination covering circulating variants.
In terms of the pharmaceutical and biotech industries, it has demonstrated the clinical value of platform technology that can easily adjust antigen composition according to changes in circulating strains. If new circulating strains are identified through global monitoring information from the Korea Disease Control and Prevention Agency (KDCA) or the World Health Organization (WHO), new multivalent formulations can be supplied within months, from sequence design to manufacturing. It possesses the potential to develop into a powerful pipeline that can be integrated into essential pediatric vaccination or regular vaccination programs for the elderly.